3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia, Myeloid, Acute
9
Leukemia
8
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Multiple Myeloma
4
Primary Immunodeficiency Diseases
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Interventions
Etoposide
7
pegaspargase
5
Methylprednisolone
4
Dexamethasone
4
Cyclophosphamide
3
Alemtuzumab
3
Gemcitabine
2
Emapalumab
2
Doxorubicin
2
zanubrutinib
1
tocilizumab
1
sintilimab
1
ruxolitinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Vincristine
1
Thiotepa
1
Tacrolimus
1
Rituximab
1
Prednisone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Methylprednisolone Hemisuccinate
1
Methotrexate
1
Melphalan
1
EPOCH protocol
1
Cytarabine
1
Cisplatin
1
Calcium Dobesilate
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphohistiocytosis, Hemophagocytic
×
AP 1903 reagent
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled